A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory CD30-positive Non-Hodgkin Lymphoma (NHL)

Status
Active
Cancer Type
Lymphoma
Trial Phase
Phase II
Eligibility
6 and over, Male and Female
Study Type
Biomarker/Laboratory analysis
Treatment
NCD ID
NCT01421667
Protocol IDs
SGN35-012 (primary)
Study Sponsor
Seattle Genetics, Incorporated

Summary

This is a single-arm, open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL).

Treatment Sites in Georgia


Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Study Coordinator:
Amanda Hutchison-Rzepka
404-778-3935

Doctors:

Christopher R. Flowers MD
Leonard T. Heffner Jr., MD
Amelia A. Langston MD
Mary Jo Lechowicz MD
Ajay K. Nooka MD, MPH